IP Library Granted Patent US 8,796,202
Granted Patent B2
US 8,796,202 · App. 13/401,642 · Granted Aug 5, 2014

Multi-valent poly-Ubl chain inhibitors and methods of use

Inventors: Yuan Chen (Arcadia, CA); David Horne (Duarte, CA); Yi-Jia Li (Duarte, CA); Yuelong Ma (Duarte, CA); Angela L. Perkins-Harki (Minneapolis, MN); Yang Su (Beijing, CN)
Assignee: City of Hope
A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,796,202
App. No.
13/401,642
Granted
Aug 5, 2014
Kind
B2
Abstract

A composition used to develop a reagent for investigating Ubl-modifications in cellular functions and in the treatment of cancer is provided. The composition comprises gold nanoparticle (AuNP)-ligand conjugates that include at least two components: gold nanoparticles (AuNPs) and modified ubiquitin- or ubiquitin-like interacting motif (UIM or ULIM) mimetics. In one embodiment, the modified ULM mimetic is a modified SUMO interaction motif (SIM) mimetic. According to the embodiments described herein, the compound inhibits ubiquitin- or ubiquitin-like protein (Ubl)-mediated protein-protein interactions and sensitizes cells to ionizing radiation. The modified UIM and ULIM mimetics may be conjugated to the AuNP such that each AuNP is conjugated to a plurality of modified UIM or ULIM mimetics. The modified ULIM mimetics may be conjugated to the AuNP via a thiol group.

Claims (13)

1. A nanoparticle attached to a plurality of peptides, wherein said peptides are each bound to a different ubiquitin-like protein in a poly-ubl chain; and wherein said peptides form part of a β sheet with each of said ubiquitin-like proteins.

2. The nanoparticle of claim 1 , wherein said peptide comprises an amino acid having a branched side chain.

3. The nanoparticle of claim 1 , wherein said amino acid is leucine, isoleucine or valine.

4. The nanoparticle of claim 1 , wherein said peptide comprises an amino acid having an aromatic side chain.

5. The nanoparticle of claim 4 , wherein said peptide comprises a tryptophan, histidine, tyrosine or phenylalanine.

6. The nanoparticle of claim 1 , wherein said peptide is bound through hydrophobic interactions to ubiquitin like protein amino acids equivalent to I33 and F31 of Sumo-3.

7. The nanoparticle of claim 1 , wherein said peptide is bound through hydrogen bonding interactions to ubiquitin like protein amino acids equivalent to K32 and K34 of Sumo-3.

8. The nanoparticle of claim 1 , wherein said peptide consists of two amino acids and a linker attaching said peptide to said nanoparticle.

9. The nanoparticle of claim 8 , wherein said nanoparticle is a metal nanoparticle and said linker comprises a sulfur atom bound to said metal nanoparticle.

10. The nanoparticle of claim 9 , wherein said linker comprises a phenyl moiety.

11. The nanoparticle of claim 10 , wherein said peptide is

wherein * represents the point of attachment of the peptide to the metal nanoparticle.

12. The nanoparticle of claim 1 , wherein said ubiquitin-like protein is a SUMO protein.

Assignments (2)
CONFIRMATORY LICENSE Recorded Nov 2, 2015
From: CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 037020/0059 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2012
From: CHEN, YUAN; HORNE, DAVID; LI, YI-JIA; MA, YUELONG; PERKINS-HARKI, ANGELA L.; SU, YANG
To: CITY OF HOPE
Reel/Frame 028781/0835 →
Continuity (2)
Provisional Application 61444634 · Feb 18, 2011
Related Publication 20120302815A1 · Nov 29, 2012